This is a working overview of alpha-MSH, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-08-25. Anything still debated is marked as such rather than presented as settled.
PT-141 initiates cellular signaling by binding to specific subtypes within the melanocortin receptor family. These receptors belong to the G protein-coupled receptor superfamily, and activation raises intracellular cyclic adenosine monophosphate levels. This cascade ultimately influences neuronal circuits in the central nervous system that are associated with sexual desire and arousal. Research indicates the compound's action concentrates in hypothalamic regions rather than peripheral tissues, which helps explain some observed pharmacological features. The selectivity of receptor binding underlies its functional differences.
Compared with the related compound melanotan II, PT-141 shows markedly weaker activation of receptors tied to pigmentation. This difference stems from subtle structural variations that alter affinity distribution across receptor subtypes. Investigators propose that such selectivity produces a different side effect profile in specific applications. However, downstream consequences of prolonged receptor activation remain uncertain in the literature. Published studies do not fully agree on the duration of signaling pathway activity and the mechanisms of desensitization.
PT-141 is the research code for bremelanotide, a cyclic heptapeptide derived from alpha-melanocyte-stimulating hormone. The molecule belongs to the melanocortin receptor agonist family and shows highest affinity for the MC4 receptor subtype, with weaker activity at MC1, MC3 and MC5. Its structure retains the core His-Phe-Arg-Trp sequence that defines melanocortin recognition, while cyclization and terminal modifications improve metabolic stability relative to the parent hormone. Early work classified the compound as a centrally acting agent rather than a peripherally acting vasodilator, which shaped subsequent development priorities.
Receptor activation in hypothalamic and limbic circuits is the mechanism most often cited for the observed effects on sexual desire. Signalling through MC4R couples to Gs proteins and raises intracellular cyclic AMP, which in turn modulates dopaminergic tone in reward-related pathways. Because the peptide reaches the central nervous system after subcutaneous administration, peripheral vascular changes are regarded as secondary rather than primary. The precise neural circuits that translate receptor occupancy into behavioural change remain incompletely mapped, and published accounts describe the pathway in general terms rather than as a fully resolved sequence.
Development began with intranasal formulations investigated for erectile dysfunction, but blood pressure elevation limited that route and prompted a switch to subcutaneous delivery. Clinical testing then shifted toward hypoactive sexual desire disorder in premenopausal women, and a subcutaneous product received United States approval in 2019. Later trials examined other populations with mixed results, and questions about effect size, durability and patient selection remain open in the peer-reviewed literature. Research interest continues in parallel with the broader melanocortin field, where several synthetic analogues are studied together.
| Property | Value | Notes |
|---|---|---|
| Primary target | Melanocortin receptors | Mainly the MC4R subtype |
| Route of administration | Injection | Typically subcutaneous |
| Time to peak | About 60 minutes | After subcutaneous dosing |
| Elimination half-life | Roughly 2 to 3 hours | Values vary across reports |
| Metabolic pathway | Peptidase hydrolysis | Cleared by the kidneys |
Bremelanotide acts as an agonist at several melanocortin receptors, with the strongest reported activity at MC4R and measurable activity at MC1R and MC3R. Because MC4R is expressed in hypothalamic and limbic circuits, the proposed mechanism links receptor activation to modulation of central pathways involved in desire rather than to direct effects on peripheral genital tissue. The precise downstream steps remain incompletely characterized, and evidence for the involvement of specific neurotransmitters is suggestive rather than settled. Nausea and blood pressure elevation reported during trials are consistent with melanocortin signaling outside the intended target circuit.
Compared with melanotan II, bremelanotide is a smaller cyclic peptide with a more constrained backbone, which affects receptor selectivity and metabolic stability. Published descriptions give a plasma half-life on the order of a few hours after subcutaneous administration, with elimination through hepatic and renal routes and limited plasma protein binding. Central access is inferred from effects observed in animal models, although direct measurement in humans is limited. Handling and storage requirements follow from the peptide backbone, which is susceptible to hydrolysis and oxidation.
Bremelanotide is a cyclic heptapeptide that acts as an agonist at melanocortin receptors. It binds MC1R, MC3R, MC4R, and MC5R, with MC4R activation considered most relevant to sexual desire pathways in the central nervous system. The molecule is a synthetic analog of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and energy regulation. Early research explored its use in tanning before attention shifted toward sexual dysfunction applications. Receptor binding affinity varies across these subtypes.
Activation of MC4R in the hypothalamus is thought to influence dopaminergic signaling, which in turn affects arousal and desire. This mechanism differs from that of phosphodiesterase type 5 inhibitors, which act primarily on vascular smooth muscle in the genital region. Because the pathway is central rather than peripheral, effects are not strictly dependent on local blood flow. The precise downstream cascade linking receptor binding to behavioral outcomes remains an area of ongoing investigation.
Clinical development of bremelanotide proceeded through several reformulation attempts. An early intranasal version was discontinued, and a subcutaneous auto-injector formulation later received approval for hypoactive sexual desire disorder in premenopausal women. Approval decisions have varied by country and over time, and the product has not been universally adopted. Blood pressure elevation is a documented effect, which is why some jurisdictions require monitoring after administration. The clinical evidence base continues to evolve as additional studies are published.
PT-141 is a synthetic cyclic heptapeptide whose development code is bremelanotide. It belongs to the class of melanocortin receptor agonists and acts by mimicking endogenous peptide hormones. The compound originated from research on melanotan II, where investigators exploring derivatives found distinct pharmacological features. Unlike the parent compound, PT-141 showed effects on pathways related to sexual desire and function in early studies, prompting its development as a separate candidate. Its molecular design aimed to separate receptor activity from pigmentary effects.
The molecular backbone consists of seven amino acid residues joined into a ring through a disulfide bridge. This cyclic conformation is critical for receptor binding. The sequence includes an acetylated N-terminus and an amidated C-terminus, modifications that improve resistance to enzymatic breakdown. One residue is in the D-configuration, a feature that further stabilizes the peptide against protease activity. Together, the ring structure and specific stereochemistry determine selectivity among melanocortin receptor subtypes.
Across literature and commercial listings, the substance appears under several names, including bremelanotide, PT-141, and various brand designations. A CAS registry number provides a unique identifier for the compound, aiding retrieval from chemical databases. Synonym lists may also contain early development codes and descriptive chemical names. When consulting sources, researchers need to confirm that the cited names refer to the same molecular structure to avoid confusion. Naming consistency matters especially when comparing analytical data across publications.
After subcutaneous dosing, peak plasma concentrations appear within roughly one hour, and elimination is fast, with a half-life on the order of a few hours. Degradation is mainly proteolytic, and at least one circulating fragment retains receptor activity, so parent-drug levels alone do not describe total exposure. Clearance does not depend heavily on hepatic cytochrome enzymes, which lowers the likelihood of common metabolic interaction routes. Data in renal or hepatic impairment are limited. Repeated dosing does not appear to produce marked accumulation given the short half-life.
Reported pharmacodynamic effects include transient rises in blood pressure and heart rate, flushing, nausea and headache, appearing soon after dosing and resolving within hours. These responses were dose-related in early studies and shaped the label's cardiovascular cautions and blood pressure monitoring advice. Gastrointestinal upset is the most frequent reason cited for discontinuation in trials. Whether the vascular signal attenuates with repeated use is not settled. Central effects on desire are described as emerging over weeks rather than immediately, which points to a cumulative rather than acute process.
Smoking or vaporizing: Using these methods, rather than injecting, is thought to reduce the risk of infections, since the high temperatures involved are more likely to kill bacteria and spores. Grinding into a powder form for snorting: This is one of the more popular ways of consuming black tar for those who do not wish to use needles. The black tar heroin is put into some sort of blender and mixed in with lactose. This creates a fine black powder product that can be easily snorted. Water looping: Water looping is when a user places the heroin in an empty eye dropper bottle, or a syringe with the needle removed. The user allows the heroin to completely dissolve into water and the solution is dropped into the nose. This at times can be wasteful if a user allows too much of the solution to go down the throat. Drinking: This is done similar to the water looping method. Instead of being delivered through the nose, the solution is swallowed. Suppository: The most effective route of administration which does not require a needle, is accomplished by delivering a solution (via syringe) or lubricated mass of the narcotic deep into the rectum or vagina.
The peaceful transition of power from Cardoso to his main opposition leader, Luiz Inácio Lula da Silva (elected in 2002 and re-elected in 2006), was seen as proof that Brazil had achieved a long-sought political stability. However, sparked by discontent accumulated over decades from corruption, police brutality, inefficiencies of the political establishment and public service, numerous peaceful protests erupted in Brazil in the middle of the first term of Dilma Rousseff, who had succeeded Lula after winning election in 2010 and again in 2014 by narrow margins. Rousseff was impeached by the Brazilian Congress in 2016, halfway into her second term, and replaced by her vice-president Michel Temer, who assumed full presidential powers after Rousseff's impeachment was accepted on 31 August. Large street protests for and against her took place during the impeachment process. The charges against her were fueled by political and economic crises along with evidence of involvement with politicians from all the primary political parties. In 2017, the Supreme Court requested the investigation of 71 Brazilian lawmakers and nine ministers of President Michel Temer's cabinet who were allegedly linked to the Petrobras corruption scandal. President Temer himself was also accused of corruption. In the fiercely contested 2018 elections, the controversial conservative candidate Jair Bolsonaro of the Social Liberal Party (PSL) was elected president, winning in the second round against Fernando Haddad, of the Workers Party (PT), with the support of 55.13% of the valid votes.
== Australian National Dictionary Centre == The Australian National Dictionary Centre has announced a Word of the Year each since 2006. The word is chosen by the editorial staff, and is selected on the basis of having come to some prominence in the Australian social and cultural landscape during the year. The Word of the Year is often reported in the media as being Australia's word of the year, but the word is not always an Australian word.
Sources: en.wikipedia.org
==== Cambodia ==== On August 30, 2021, 7-Eleven and Thailand's Charoen Pokphand opened the first 7-Eleven store in Phnom Penh's Chroy Changvar district. The company hinted at plans to open at least six more stores in Phnom Penh in 2021. According to plans, products from local small- and medium-sized enterprises (SME) sold in 7-Eleven in Cambodia will comprise at least 50 percent of the stock.
This site includes an abundance of bedrock mortars, which were used for grinding and crushing of organic materials. Apart from maize, there is evidence of using the mortars for trees, beans, fruits, and animal bones. In regards to chicha, archaeologists believe the workforce at the mortars was predominantly female, considering chicha production is associated with feminine roles. The wide variety of materials used, and the large number of present mortars, demonstrates the location’s important role as a place of mass production. Chicha production sites, like El Shincal, demonstrate the complex production dedicated to preparing for successful and extravagant ceremonial celebrations that revolve around chicha consumption. Additional preparation methods, such as mixing, soaking, or drying, vary plenty depending on the food, and often use a wide variety of vessels to cater to the specific method. Preparation methods will continue to evolve with time as new ways are discovered and adapted with changing availability to resources. Adaptation and flexibility are essential to prioritizing how culinary practices are carried out to best represent the cultural values held by a community.
=== Applications in proteomics === In proteomics, the study of the full set of proteins expressed by a genome, identifying diseases biomarkers can involve the usage of stable isotope labeling by amino acids in cell culture (SILAC), that provides isotopic labeled forms of amino acid used to estimate protein levels. In protein recombinant, manipulated proteins are produced in large quantities and isotope labeling is a tool to test for relevant proteins. The method used to be about selectively enrich nuclei with 13C or 15N or deplete 1H from them. The recombinant would be expressed in E.coli with media containing 15N-ammonium chloride as a source of nitrogen. The resulting 15N labeled proteins are then purified by immobilized metal affinity and their percentage estimated. In order to increase the yield of labeled proteins and cut down the cost of isotope labeled media, an alternative procedure primarily increases the cell mass using unlabeled media before introducing it in a minimal amount of labeled media. Another application of isotope labeling would be in measuring DNA synthesis, that is cell proliferation in vitro. Uses H3-thymidine labeling to compare pattern of synthesis (or sequence) in cells.
The degree of its adherence to feng shui is believed to determine a business's success. Bagua mirrors are regularly used to deflect evil spirits, and buildings often lack floor numbers with a 4; the number has a similar sound to the word for "die" in Cantonese.
Sources: en.wikipedia.org
It primarily activates specific subtypes in the melanocortin receptor family. These receptors are G protein-coupled and mediate signaling mainly within the central nervous system.
It activates pigmentation-related receptors more weakly. This selectivity is thought to alter its side effect profile.
Injection is the most common route. Nasal administration has been studied as well, though absorption varies considerably.
The code designates bremelanotide, a cyclic heptapeptide melanocortin receptor agonist. It served as an internal research identifier before the compound entered formal clinical development. The code and the generic name refer to the same molecule.